In a patient with severe asthma who requires a 200 µg dose of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) but only the 100 µg strength is available, should two inhalations be administered to achieve the required dose?

Do Not Give Two Inhalations of Trelegy 100 to Achieve a 200 µg Dose

You cannot and should not administer two inhalations of Trelegy Ellipta 100/62.5/25 µg to achieve the 200 µg fluticasone furoate dose. This approach would result in a dangerous overdose of umeclidinium (125 µg instead of 62.5 µg) and vilanterol (50 µg instead of 25 µg), which are fixed-dose components in the triple therapy inhaler 1.

Why This Is Contraindicated

Trelegy Ellipta is a fixed-dose triple combination containing three medications in precise ratios 1:

• Fluticasone furoate (ICS): 100 or 200 µg
• Umeclidinium (LAMA): 62.5 µg (fixed)
• Vilanterol (LABA): 25 µg (fixed)

The FDA label explicitly states: "More frequent administration or a greater number of inhalations (more than 1 inhalation daily) of the prescribed strength of Trelegy Ellipta is not recommended as some patients are more likely to experience adverse effects with higher doses" 2. Doubling the dose would expose the patient to:

• Double the anticholinergic load (125 µg umeclidinium), increasing risks of urinary retention, narrow-angle glaucoma exacerbation, and cardiovascular effects 1
• Double the LABA dose (50 µg vilanterol), increasing risks of tachycardia, tremor, hypokalemia, and potential cardiac arrhythmias 1

What to Do Instead

Immediate Management Options:

1. Prescribe the correct strength: Obtain Trelegy Ellipta 200/62.5/25 µg through appropriate channels (pharmacy transfer, manufacturer assistance programs, or alternative supplier) 1

2. Bridge therapy while awaiting correct dose: If the patient requires immediate treatment and only the 100 µg strength is available:

   • Continue current ICS/LABA therapy at appropriate dose
   • Add separate umeclidinium 62.5 µg inhaler if triple therapy is indicated
   • This maintains appropriate dosing of all components until the correct Trelegy strength is obtained

3. Re-evaluate the dose requirement: Consider whether the patient truly requires 200 µg versus 100 µg fluticasone furoate:

   • For patients stepping up from low-medium dose ICS/LABA: Trelegy 100/62.5/25 µg may be sufficient 1
   • For patients on high-dose ICS/LABA with inadequate control: Trelegy 200/62.5/25 µg is appropriate 1, 3
   • The CAPTAIN trial showed both doses were effective, with the 200 µg dose providing greater exacerbation reduction in patients with elevated type 2 inflammatory biomarkers 3

Clinical Decision Algorithm:

If patient has severe asthma with:

• Blood eosinophils >300 cells/µL OR
• FeNO >50 ppb OR
• Frequent exacerbations (≥2/year) on current therapy

→ Must obtain 200 µg strength; do not compromise with doubled 100 µg dose

If patient has moderate asthma with:

• Lower eosinophil counts
• Infrequent exacerbations
• Primarily symptomatic control issues

→ Consider initiating 100 µg strength while arranging for 200 µg if clinically indicated 3

Critical Safety Considerations

The evidence shows that LABA overdose carries significant risks. Guidelines consistently emphasize using LABAs only at recommended doses 4. Anticholinergic overdose with umeclidinium can cause:

• Acute urinary retention (especially in elderly males with prostatic hyperplasia) 1
• Acute angle-closure glaucoma 1
• Cardiovascular effects including tachycardia and palpitations 5

Never attempt to achieve a higher ICS dose by doubling a fixed-dose combination inhaler that contains other active medications. This fundamental principle applies to all combination inhalers, not just Trelegy.